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ABSTRACT  24 
The steroid disulfates (aka  bis-sulfates or bis(sulfates)) are a significant but minor 25 
fraction of the urinary steroid metabolome that have not been widely studied 26 
because major components are not hydrolyzed by the commercial sulfatases 27 
commonly used in steroid metabolomics. In early studies, conjugate fractionation 28 
followed by hydrolysis using acidified solvent (solvolysis) was used for the indirect 29 
detection of this fraction by GC-MS. This paper describes the application of a specific 30 
LC-MS/MS method for the direct identification of disulfates in urine, and their use as 31 
markers for the prenatal diagnosis of disorders causing reduced estriol production: 32 
STSD (Steroid Sulfatase Deficiency), SLOS (Smith-Lemli-Opitz Syndrome) and PORD 33 
(P450 Oxido-Reductase Deficiency). Disulfates were detected by monitoring a 34 
constant-ion-loss (CIL) from the molecular di-anion. While focused on disulfates, our 35 
methodology included an analysis of intact steroid glucuronides and monosulfates 36 
because steroidogenic disorder diagnosis usually requires an examination of the 37 
complete steroid profile. In the disorders studied, a few individual steroids (as 38 
disulfates) were found particularly informative: pregn-5-ene-3β,20S-diol, pregn-5-39 
ene-3β,21-diol (STSD, neonatal PORD) and 5α-pregnane-3β,20S-diol (pregnancy 40 
PORD). Authentic steroid disulfates were synthesized for use in this study as aid to 41 
characterization. Tentative identification of 5ξ-pregn-7-ene-3ξ,20S-diol and 5ξ-42 
pregn-7-ene-3ξ,17,20S-triol disulfates was also obtained in samples from SLOS 43 
affected pregnancies. Seven ratios between the detected metabolites were applied 44 
to distinguish the three selected disorders from control samples. Our results show 45 
the potential of the direct detection of steroid conjugates in the diagnosis of 46 
pathologies related with steroid biosynthesis. 47 
 48 
49 
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INTRODUCTION 50 
From the earliest days of steroid metabolomics, the principal conjugated forms of 51 
steroids (sulfates and glucuronides) have been hydrolyzed prior to analysis, and for 52 
decades the instrument of choice for steroid separation and measurement has been 53 
GC-MS (Shackleton and Marcos 2006). While this technique remains the gold-54 
standard for steroid profiling, LC-MS/MS has been increasingly adopted because of 55 
the simplified sample preparation and speed of analysis, mainly provided by 56 
absence of a derivatization step. This is in spite of the poor ionization for fully 57 
reduced steroids by electrospray (ESI) (Pozo, et al. 2007).  While an advance, this 58 
methodology still retains the most time-consuming step of sample preparation, the 59 
enzymatic or chemical hydrolysis of conjugates (Gomes, et al. 2009). Hydrolysis itself 60 
can take several hours and requires a further solid phase extraction (SPE). Necessary 61 
chemical derivatization for GC-MS can also take hours. 62 
Intact steroid conjugates have been analyzed by mass spectrometry since the 63 
introduction of particle beam ionization (e.g. Fast Atom Bombardment, FAB) in the 64 
1980s (Shackleton and Straub 1982; Shackleton 1983). Their spectra have dominant 65 
deprotonated molecules [M-H]- in negative ion mode allowing ease of mass 66 
determination. Conjugate analysis was simplified with the introduction of 67 
electrospray ionization (ESI) and incorporation of HPLC and MS/MS. Glucuronides 68 
can be analyzed in both positive and negative ionization modes by monitoring 69 
[M+NH4]
+ and [M-H]- respectively (Fabregat, et al. 2013). In the case of 70 
monosulfates, collision-induced-dissociation (CID) of the strong [M-H]- ions shows a 71 
distinctive hydrogen sulfate (HSO4
-) fragment at m/z 97 (Shackleton 1983; Galuska, 72 
et al. 2013). Direct detection of steroid conjugates also circumvents the ionization 73 
problems of reduced steroids (Pozo, et al. 2007) as phase II metabolites have readily 74 
ionized functionality (i.e. a carboxylic acid in glucuronides and an acidic sulfate ester 75 
in sulfates).  76 
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While mono-conjugates dominate the sulfate fraction of urinary steroids, it has been 77 
known since the 1960s that disulfates (diS, also referred to as bis(sulfates) or bis-78 
sulfates to distinguish them from compounds containing the disulfate (S2O7
2-) unit) 79 
are significant components of the metabolome (Pasqualini and Jayle 1962; Arcos 80 
and Lieberman 1967; Shackleton, et al. 1968a; Shackleton, et al. 1968b; Jänne, et al. 81 
1969). Early studies by GC-MS of separated conjugate fractions showed that, in 82 
addition to the classic 3β-sulfated steroids, hydroxyls at positions 16β-, 17-(α and β) 83 
and 18- in androgens and 20- and 21- in pregnanes were prone to sulfation (Jänne, 84 
et al. 1969; Jänne and Vihko 1970; Laatikainen, et al, 1972; Meng and Sjövall 1997).  85 
Since these original studies, disulfates have been a largely ignored component of the 86 
metabolome that nevertheless had significant potential to expand the 87 
understanding of steroid biosynthetic and metabolic pathways. Given this, we 88 
sought to develop LC-MS/MS methodology to target this group. It was found that 89 
constant-ion-loss (CIL) of hydrogen sulfate (HSO4
-) fragment at m/z 97 from the 90 
molecular di-anion [M-2H]2- was the most useful reaction to monitor (McLeod, et al. 91 
2017). 92 
The ease of steroid disulfate analysis led us to investigate their use in diagnosis of 93 
steroid biosynthetic disorders. One particular area of interest to the authors has 94 
been the pre-natal diagnosis of single-gene disorders of estriol (E3) synthesis by 95 
urine analysis, of which we have studied three conditions by GC-MS, viz., Steroid 96 
Sulfatase Deficiency (STSD), Smith-Lemli-Opitz Syndrome (SLOS, 7-dehydrosterol 97 
reductase deficiency) and cytochrome P450 Oxido-Reductase Deficiency (PORD) 98 
(Marcos et al. 2009; Shackleton, et al. 2004a; Shackleton et al. 2004b; Arlt et al. 99 
2004; Reisch, et  al. 2013; Shackleton et al. 2007). This communication offers our 100 
preliminary observations of the disulfated steroids excreted in these disorders at 101 
around mid-pregnancy. While focusing on disulfates, selected monosulfates and 102 
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glucuronides were also included; evaluating the complete steroid profile is crucial to 103 
diagnosing aberrant steroid biosynthesis (Shackleton and Marcos 2006). 104 
105 
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MATERIALS AND METHODS 106 
 107 
Reagents and chemicals 108 
 109 
Steroid starting materials were obtained from Steraloids (Newport, RI, USA). 110 
Chemicals and solvents including sulfur trioxide pyridine complex (SO3.py), N,N-111 
dimethylformamide (DMF) and ammonium formate (HPLC grade) were purchased 112 
from Sigma–Aldrich (St Louis, MO, USA). Aqueous ammonia solution (25%), and 113 
acetonitrile and formic acid (LC-MS grade) were from Merck (Darmstadt, Germany). 114 
MilliQ water was obtained using a Milli-Q purification system (Millipore Ibérica, 115 
Barcelona, Spain). 116 
 117 
Synthesis of reference steroid disulfates  118 
 119 
The qualitative synthesis of steroid disulfates as the ammonium salts was performed 120 
as previously described (McLeod, et al. 2017) with small modifications. Briefly, 1 mg 121 
of each steroid standard was directly dissolved in a freshly prepared solution of 122 
SO3.py complex (20 mg, 124 μmol, ~38 eq/steroid or ~19eq/hydroxyl group) in DMF 123 
(100 µL) and incubated at room temperature for 72 hours. The success of synthesis 124 
was confirmed by analysis of reaction using both LC-MS in scan mode and LC-MS/MS 125 
for collision induced dissociation studies. The purification of synthesised disulfates 126 
was performed using SPE as previously described (McLeod et al, 2017).  127 
Steroid disulfate reference materials isolated as the corresponding ammonium salts 128 
and used in this study included: 5α-pregnane-3β,20S-diol bis(sulfate), (3β5αPD-diS); 129 
3β,21-dihydroxypregn-5-en-20-one bis(sulfate), (21-hydroxypregnenolone 130 
bis(sulfate),  21OHPreg-diS); androst-5-ene-3β,17α-diol bis(sulfate), (5AD(17α)-diS); 131 
androst-5-ene-3β,17β-diol bis(sulfate), (5AD(17β)-diS); 3β,16α-dihydroxyandrost-5-132 
en-17-one bis(sulfate), (16α-hydroxydehydroepiandrosterone bis(sulfate), 133 
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16αOHDHEA-diS); 3β,16β-dihydroxyandrost-5-en-17-one bis(sulfate) (16β-134 
hydroxydehydroepiandrosterone bis(sulfate), 16βOHDHEA-diS); pregn-5-ene-135 
3β,17α,20S-triol 3,20 bis(sulfate), (5PT-diS); pregn-5-ene-3α,20S-diol bis(sulfate), 136 
(5PD-diS); 5β-pregnane-3β,20S-diol bis(sulfate),; 5β-pregnane-3α,20S-diol 137 
bis(sulfate),; 5α-pregnane-3α,20S-diol bis(sulfate),; 5β-pregnane-3β,20R-diol 138 
bis(sulfate), 5α-pregnane-3β,20R-diol bis(sulfate),; 5β-pregnane-3α,20R-diol 139 
bis(sulfate),;  In this manuscript the IUPAC terms for the 20-hydroxypregnane 140 
diastereomers are used, S and R, in some publications often trivialized to α and β, 141 
respectively. 142 
Two reference materials (3β5αPD-diS and 21OHPreg-diS), were prepared on larger 143 
scale and subjected to characterisation by spectroscopic methods. Experimental 144 
details and characterization data for these new compounds, together with copies of 145 
the 1H NMR, 13C NMR, and ESI LRMS spectra are available from the authors (MM). 146 
 147 
Urine Samples 148 
One of our laboratories (Children’s Hospital Oakland, Dr. Cedric Shackleton) has 149 
been the recipient for urine samples from patients with suspected abnormal 150 
steroidogenesis in an attempt to characterize the defects. The studies were 151 
approved by the Children’s Hospital Institutional Review Board (IBR#2010-038)). 152 
Many of the samples used in this study were remnants of those sent to the 153 
laboratory for investigation of low pregnancy estriol (generally defined as individuals 154 
with serum unconjugated estriol < 0.3 MoM, multiples of median). Other samples 155 
were from women who had had a previously affected SLOS child or other 156 
symptomatic reasons for concern regarding steroidogenesis. The samples have 157 
generally been collected between week 16 and 30 of gestation.  They have been 158 
stored frozen at -20 °C. Eleven STSD samples were analyzed, and six samples from 159 
SLOS affected pregnancies. The neonatal PORD samples were collected at 7, 18 and 160 
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23 days. Urine samples from unaffected pregnancies were from a collection held by 161 
IMIM (Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona). Normal 162 
neonatal urine specimens were from a control urine collection at the Institute of 163 
Metabolism and Systems Research (IMSR), University of Birmingham UK. 164 
 165 
 166 
Sample treatment  167 
Urine extraction was by C18 SPE. Generally, a 2 mL aliquot of urine was passed 168 
through a pre-conditioned cartridge. After a washing step with 3 mL water, steroid 169 
conjugate analytes were eluted using 2 mL of methanol. After evaporation of a 200 170 
µL aliquot of the elution solvent, the extract was reconstituted in 100 µL of water 171 
and 5 µL was injected into the UHPLC-MS/MS system. Stably labelled 17-S{18O}3-5α-172 
androstane-3α,17β-diol 3,17-bis(sulfate) and 17-S{18O}3-5α-androstane-3β,17β-diol 173 
bis (sulfate) were used as internal standards. The labeled sulfate residue was 174 
introduced to the steroidal diol mono-sulfate using labelled S{18O}3.py generated in 175 
situ from labelled sulfuric acid (95% atom) and acetic anhydride in pyridine. 176 
Experimental details and characterization data for these internal standards, together 177 
with copies of the 1H NMR, 13C NMR, and ESI LRMS spectra are available from the 178 
authors (MM) 179 
 180 
UHPLC-MS/MS analysis 181 
 182 
Disulfates 183 
 184 
The study was carried out using a triple quadrupole (XEVO TQ-S micro) mass 185 
spectrometer equipped with an ESI source and interfaced to an Acquity UPLC system 186 
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for the chromatographic separation (all from Waters Associates, Milford, MA, USA). 187 
Drying gas as well as nebulizing gas was nitrogen. The desolvation gas flow was set 188 
to approximately 1200 L/h, and the cone gas flow was 50 L/h. A cone voltage of 30 V 189 
and a capillary voltage of 0.4 kV were used in negative ionization mode. The 190 
nitrogen desolvation temperature was set to 600 °C, and the source temperature 191 
was 150 °C. 192 
The UHPLC separation was performed using an Acquity UPLC CSH Phenyl-Hexyl 193 
column (2.1 × 100 mm i.d., 1.7 μm) (Waters Associates), at a flow rate of 300 194 
μL/min. Water and acetonitrile:water (9:1) both with formic acid (0.01% v/v) and 195 
ammonium formate (25 mM) were selected as mobile phase solvents. A gradient 196 
program was used; the percentage of organic solvent was linearly changed as 197 
follows: 0 min, 15%; 0.5 min, 15%; 25 min, 30%; 26 min, 100%; 27 min, 100%; 28 198 
min, 15%; 30 min, 15%. The total analysis time was 30 min. 199 
For the constant ion loss (CIL) scan, dwell times of 6 ms and collision energies of 15 200 
eV were selected for each ion transition. Due to the molecular masses of steroid 201 
hormones and metabolites (250-400 Da), the precursor ions of disulfates ([M-2H]2-) 202 
were restricted to the range from m/z 199 to m/z 274. A Selected Reaction 203 
Monitoring (SRM) approach containing 75 preselected transitions was used for the 204 
simultaneous detection of steroid disulfates. Among them, the transition 228→359 205 
corresponded to the internal standards used in the analysis.  206 
 207 
Monoconjugates 208 
 209 
While the focus has been on steroid disulfates we have acquired data on steroid 210 
monosulfates and glucuronides previously reported as relevant for the studied 211 
disorders. Based on previous studies (Gomez, et al. 2014) the product ions at m/z 97 212 
and m/z 75 for sulfates and glucuronides respectively were chosen (Table 1). 213 
Exceptions were estriol conjugates due to the influence of the aromatic ring. The 214 
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neutral loss of the conjugate (80 Da and 176 Da for sulfates and glucuronides 215 
respectively were detected).  216 
 217 
Quantification 218 
For this study, accurate quantitative measurements have not been conducted for 219 
two reasons: 1) lack of some authentic compounds prevented the determination of 220 
relative responses of analyte transitions to internal standard transitions; 2) the urine 221 
samples were random “spot” collections and not accurate 24 h collections. Instead, 222 
we have determined “diagnostic-ratios” from raw mass spectrometric transition 223 
responses. These ratios are of an analyte known to be overproduced to one known 224 
to be underproduced in a particular disorder. Such ratios have long been used in GC-225 
MS analysis (Shackleton and Marcos,2006). 226 
 227 
228 
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RESULTS AND DISCUSSION 229 
 230 
Method development 231 
This communication applies recent LC-MS/MS studies on steroid disulfate analysis 232 
using the constant-ion-loss (CIL) from the di-anionic precursor [M-2H]2- (McLeod, et 233 
al. 2017). The method was developed for untargeted detection, and designed for 234 
the analysis of a maximum number of natural disulfates. The use of this precursor 235 
ion and the fact that the product ion has a higher m/z value is unusual for small 236 
molecules. Determination of disulfates under these conditions gives clean 237 
chromatograms and the main interferences observed in the chromatograms are due 238 
to the relatively high natural abundance of the 34S isotope (4.25%). The transition 239 
coming from the m/z 97 loss from an unsaturated (∆4, ∆5, etc.) {34S}1-disulfate 240 
isotope is completely indistinguishable from the one coming from an A-ring reduced 241 
steroid disulfate.  242 
To maximize isobaric steroid metabolite separation (e.g. pregnenediol-diS, the 243 
pregnanediol-disulfates and the androstenediol-disulfates) in this study, a phenyl-244 
hexyl column with a relatively high amount of ammonium formate (25 mM) was 245 
required to obtain sharp and well resolved chromatographic peaks. Column 246 
temperature was critical for this purpose with 30 °C determined as optimum. Under 247 
these conditions, a 25 min gradient from 15% to 30% of organic solvent provided 248 
desired separation (Figure 1A). 249 
Under optimized conditions the elution order of disulfates was 250 
dihydroxyandrostanones < dihydroxypregnanones < androstenediols < 251 
pregnanediols. In a specific group, 17β hydroxysteroid disulfates eluted earlier than 252 
their 17α-counterparts and 20S-hydroxysteroid disulfates eluted earlier than their 253 
20R counterparts. Regarding A ring derivatives, ∆5 steroid disulfates eluted before 254 
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the fully reduced metabolites, the elution order of the reduced steroids being 3β,5β 255 
< 3β,5α < 3α,5β < 3α,5α. The chromatographic conditions were also able to separate 256 
the two estriol glucuronide isomers i.e. the 16-glucuronide and 3-glucuronide. 257 
Unfortunately, sulfate and glucuronide conjugates of two useful steroids in PORD 258 
diagnosis, androsterone and etiocholanolone, could not be separated under the 259 
selected conditions even after increasing the gradient to 1 h (Figure 1B).  260 
 261 
 262 
Application to prenatal detection of disorders affecting estriol synthesis 263 
We report preliminary studies to determine whether steroid disulfates in urine can 264 
be useful markers in the prenatal detection of disorders affecting estriol synthesis; 265 
until now only monoconjugates had been used. The background to this study being 266 
that unconjugated serum E3 is frequently measured at mid-pregnancy as a marker 267 
for Down’s syndrome as part of a test called triple- or quad- marker screening 268 
(Haddow, et al. 1994). If results are low the question remains as to the reason, and 269 
our original research was directed to diagnosis of Smith-Lemli-Opitz Syndrome 270 
(SLOS), the clinically most severe cause of low E3 (Shackleton, et al. 2007). These 271 
studies led to investigation of other causes such as STSD and PORD.  272 
Diagnostic ratios are frequently employed in steroid metabolomics and E3 273 
frequently used as denominator. Dominant E3 conjugates are 3- and 16-274 
glucuronides (30% and 60%, respectively) with about 2.5% as monosulfate and 275 
estriol-3-glucuronide-16-sulfate (6.5%) (Tikkanen, et al. 1973). We assessed E3 276 
excretion from the measurement of glucuronide and monosulfate conjugates (Table 277 
1).  278 
 279 
Steroid sulfatase deficiency (STSD) (OMIM , 308100, location, Xp22.31) 280 
 281 
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This X-linked disorder prevents the release of steroid from steroid sulfates.  A 282 
summary of the biosynthetic pathway leading to estriol is shown in Figure 2, 283 
illustrating that inactivity of the enzyme in placenta prevents 16αOHDHEA-S 284 
conversion to E3. This fetal 16αOHDHEA-S, androst-5-ene-3β,16α,17β-triol sulfate 285 
(5AT-S) and other steroid sulfates pass through the placenta and mother to be 286 
excreted in urine largely unchanged (Taylor and Shackleton, 1979). 287 
 288 
STSD urine samples (N=11) and 11 controls were analyzed using the CIL scan method 289 
for disulfates complemented with the acquisition of 16αOHDHEA-S and E3 290 
monoconjugates (Table 1). Among the disulfates measured by the CIL method, we 291 
found that the response ratio between six of them, namely 16αOHDHEA-diS, 292 
5AD(17α)-diS, 5AD(17β)-diS, 5PT-diS, 21OHPreg-diS and 5PD-diS against E3 293 
glucuronide (measured as sum of 3- and 16-glucuronides) was markedly increased in 294 
STSD.  295 
 296 
Representative chromatograms of a normal pregnancy urine and one with an STSD 297 
affected fetus are shown in Figure 3. The ratio values for our normal and STSD data 298 
sets are shown in Figure 4A and show all analytes clearly distinguish STSD from 299 
normal. Additionally, we used the ratios to evaluate the relative efficacy of each 300 
analyte in diagnosis. The best steroid discriminatory ratio would show greatest 301 
difference between the lowest steroid sulfate/E3-G ratio value in STSD, and the 302 
highest ratio found in controls (Figure 4B). Interestingly, the ratios that gave the 303 
greatest differential were ∆5 pregnenes; 5PD-diS, 5PT-diS and 21OHPreg-diS, not the 304 
C19 steroid sulfates on the direct biosynthetic pathway to E3. Combining ratio data 305 
can give an even greater separation for normal and affected; note the combined 306 
data for 21OHPreg-diS and 5PD-diS in Figure 4C. Such pregnene metabolites should 307 
be incorporated in MS based methodologies for detection of the disorder. 308 
 309 
P450 oxido-reductase deficiency (PORD) (POR OMIM 124015 location: 7q11.23) 310 
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 311 
Several pregnant women carrying PORD fetuses have been studied by GC-MS 312 
(Shackleton, et al. 2004; Reisch, et al. 2013), but for only two were samples available 313 
for this study. Shackleton and co-workers (2004a) deduced that the dominant “feto-314 
placental” maternal urinary steroid in PORD pregnancies was 3β5αPD-diS. While this 315 
steroid is also present in the disulfate fraction of normal pregnancy urine it is in 316 
much greater amount in PORD affected pregnancies. From its dominance together 317 
with reduced E3, it was concluded that this metabolite is a maternal excretory 318 
product of fetal pregnenolone. An intermediate precursor would be fetal steroid 319 
5PD-diS. Excess pregnenolone and its sulfate are the result of an apparent “block” in 320 
17-hydroxylase/C17-20 lyase secondary to attenuated POR activity (Figure 5). This 321 
block, together with suppressed 16α-hydroxylase (also due to PORD) causes 322 
reduction of fetal 16αOHDHEA-S production leading to low maternal E3 production 323 
and excretion. The precise sequence of reactions from fetal pregnenolone to 324 
3β5αPD-diS, and localities of the conversions (fetal adrenal, liver, placenta and 325 
mother) is yet to be determined. The process is multi-step, probably including 326 
placental 3β-desulfation and likely 3β-hydroxysteroid dehydrogenase/isomerase. It 327 
has long been known that both 3β5αPD-diS and 5PD-diS are prominent disulfates in 328 
umbilical cord blood (Laatikainen, et al. 1972) so are freely synthesized and 329 
transported in the feto-placental unit. The synthetic sequence for pregnenolone 330 
conversion to urinary metabolites in normal and PORD affected pregnancies and 331 
neonate are shown in Figure 5. Evidence suggests the corresponding conversion of 332 
pregnenolone sulfate to DHEA-S is not an available pathway (Neunzig, et al. 2014; 333 
Sanchez-Guijo, et al. 2016; Rege, et al. 2017). 334 
Besides the increased excretion of 3β5αPD-diS, we also observed an increase in the 335 
transitions corresponding to 5PD-diS and 3β,21-dihydroxy-5α-pregnan-20-one 336 
disulfate (21OHPreg3β5α-diS), the latter in spite of a likely POR requirement by fetal 337 
21-hydroxylase. However, it should be noted that this fetal enzyme differs from that 338 
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coded by CYP21A2 required in cortisol synthesis (Guerami et al., 1988, Corsan, 339 
Macdonald and Casey., 1997).  340 
In Figure 6 we illustrate the chromatographic profiles of the 3β5αPD-diS, 5PD-diS 341 
and 21OHPreg3β5α-diS and the E3 conjugates in a control (Figure 6A) and affected 342 
pregnancy (Figure 6B). The dominance of the 3β5αPD-diS in the affected 343 
pregnancies is striking. In GC-MS diagnosis of PORD prenatally the ratio of 344 
3β5αPD/E3 was used, i.e. the ratio of principal PORD fetal metabolite to E3, the 345 
conventional feto/maternal metabolite. In Figure 6C are shown ratios for intact 346 
conjugates in PORD and controls. For the denominator (E3) we summed the total of 347 
both glucuronylated forms.  348 
 349 
One of the GC-MS prenatal diagnostic ratios for PORD remains a challenge for LC-350 
MS/MS under conditions developed for this study. With fetal PORD there is 351 
increased androsterone production as a result of the “alternative pathway” activity 352 
(Arlt, et al. 2004) resulting in markedly increased androsterone/etiocholanolone 353 
ratio (Shackleton et al 2004a). That ratio should theoretically be determined by 354 
direct analysis of glucuronides and this separation has been already reported by C18 355 
columns both in glucuronides (Pozo et al. 2008) and unconjugated (Marcos and 356 
Pozo, 2016). Unfortunately, under current chromatographic conditions developed 357 
for the disulfates such isobaric monoconjugates (sulfates or glucuronides) could not 358 
be resolved.  359 
 360 
Postnatal detection of PORD:  361 
 362 
While this paper has focused on prenatal diagnosis of PORD by 3β5αPD-diS 363 
measurement, Shackleton and co-workers (Shackleton et al. 2004b) have shown 364 
that its precursor 5PD-diS is a key analyte in diagnosing the condition in the first 365 
months of life suggested its inclusion here. In PORD neonatal samples this steroid is 366 
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dominant, excretory values exceeding the classical major metabolites such as 367 
16αOHDHEA-S and 16α-hydroxypregnenolone sulfate whose biosynthesis by 16α-368 
hydroxylation is also POR dependent. In the first weeks of life the fetal zone of the 369 
adrenal is still dominant, but diminishing, and is responsible for producing a large 370 
amount of 3β-OH-∆5 steroids.  371 
Figure 7 illustrates the separation of steroid disulfates in an affected PORD infant 372 
and normal infant. We have included 16αOHDHEA-S as analyte to act as 373 
denominator for a potential diagnostic ratio 5PD-diS/16αOHDHEA-S. This ratio is 374 
shown for three affected infants and normal controls in Figure 7C, clearly defining 375 
the condition. Interestingly, one of the first steroid disulfates to be identified in the 376 
neonatal period were 5AD(17α and 17β)-diS (Shackleton, et al. 1968a, Laatikainen, 377 
et al. 1972), and 16βOHDHEA-diS (Shackleton, et al. 1968b, Laatikainen, et al. 1972) 378 
and these are clearly separated with this methodology (Figure 7). 379 
 380 
Smith-Lemli-Opitz Syndrome. “7-dehydrosterol reductase” deficiency. (SLOS) (OMIM 381 
602858 location: 11q13,4) 382 
 383 
This condition is caused by deficiency in 7-dehydrosterol reductase and the notable 384 
feature is a build-up of 7-and 8-dehydrocholesterol, which can be used to diagnose 385 
the condition when measured in amniotic fluid (Kelley,1994). The affected fetus can 386 
use these sterols as steroid precursors, resulting in the appearance in maternal urine 387 
of dehydro (DH) versions of common natural steroids. For instance, 5β-pregn-7(and 388 
8)-ene-3α,17α,20S-triol, (7(8)-DHPT) and an estriol equivalent, principally 8-389 
dehydroestriol (8-DHE3) (Guo, et al. 2001, Shackleton, et al. 1999). The biosynthesis 390 
of steroids in SLOS pregnancy is illustrated in Figure 8.  391 
SLOS steroids are mainly excreted as glucuronides. Thus, distinct peaks 392 
corresponding to different isomers of 8-DHE3-G were found in all SLOS samples 393 
(Figure 9). On the other hand, the detection of 7(8)-DHPT-G provided more 394 
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difficulties due to endogenous interferences probably coming from other 395 
pregnenetriols and DH-hydroxypregnenolones which would share the same 396 
transition (Figure 9).  397 
 398 
A systematic study has not been made of steroid sulfates in this condition and lack 399 
of appropriate authentic compounds has meant that only candidate 400 
chromatographic peaks were provisionally identified. Such peaks were chosen by 401 
having the expected CIL transitions for steroids with additional unsaturation and to 402 
be accepted as SLOS-specific “candidate” analytes these peaks had to be present in 403 
all six confirmed SLOS pregnancies, and be absent from controls. Two main 404 
metabolites were found. Peaks with the expected transitions for DHPT-diS and 405 
DHPD-diS were observed in all SLOS samples. Additionally, other minor metabolites 406 
such as DH-androstenediol-diS were also found. In Figure 9 the chromatograms of 407 
the proposed steroid disulfate analytes with DH-pregnanetriol glucuronide and 408 
DHE3-glucuronide are shown. Little information can be stated on stereochemistry of 409 
candidate analytes; not only that of 3- and 5-positions but both ∆7 and ∆8 isomers 410 
are likely present. The chromatograms illustrated were from one affected pregnancy 411 
and one control. Similar chromatograms were produced for the other five affected 412 
pregnancies and controls. Clearly this is the most challenging of the three conditions 413 
for conjugate LC-MS/MS analysis although aberrant steroid conjugate peaks 414 
definitive for SLOS were detected. 415 
 416 
Distinguishing the disorders: summary 417 
 418 
This study has focused on the mass spectrometric analysis of steroid disulfates, but 419 
steroid monosulfates and glucuronides have been included where required to 420 
determine ratios used for diagnosis. In order to evaluate the potential of the 421 
approach based on the combined screening of glucuronides, monosulfates and 422 
disulfates, we propose a panel of markers able to differentiate between the selected 423 
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disorders and control samples. We found that using the ratios 16αOHDHEA-S/E3-G, 424 
3β5αPD-diS/E3-G, 5PD-diS/16αOHDHEA-S, 21OHPreg-diS/E3-G, 21OHPreg-425 
diS/16αOHDHEA-S, 8DHE3-G/E3-G and DHPT-diS/E3-G allowed for the successful 426 
differentiation between the controls and the different disorders 427 
Hopefully the study emphasizes the potential of LC-MS analysis of all conjugate 428 
types in future development of steroid metabolomics. 429 
 430 
General discussion 431 
 432 
The steroid disulfates are a minor fraction of the urinary steroid metabolome, but 433 
may provide significant markers of aberrant steroid biosynthesis. As a family, intact 434 
steroid disulfates have not been recently subject to detailed study due a lack of 435 
suitable analytical methodology. In the past, studyingthis family always involved 436 
time-consuming fractionation of free and conjugate families followed by solvolysis 437 
and GC-MS analysis. Most of the available literature stems from the 60’s and 70’s 438 
and it was shown early which secondary positions (assuming the primary sulfated 439 
position is the 3-hydroxyl) could be sulfated. These were 17 (α-and β), 16β- and 18 440 
in C19 steroids and 20S- and 21- in C21 steroids. During that early research period the 441 
dominant biological materials chosen to study were associated with pregnancy. In 442 
that respect our current studies have followed this lead and the major disulfate 443 
components reported here were also noted in the early publications (Shackleton, et 444 
al. 1968a; Shackleton, et al. 1968b; Jänne, et al. 1969; Jänne and Vihko 1970; 445 
Laatikainen et al 1972; Meng and Sjövall 1997). 446 
 447 
There is little definitive evidence as to which sulfotransferases are responsible for 448 
the secondary sulfation (Mueller et al 2015), and how disulfates are transported 449 
(Grosser et al 2017). Available sulfation evidence points solely to SULT2A1 which 450 
appears to have an active site capable of encompassing a wide variety of steroid 451 
substrates (both free and monosulfated) and conduct sulfation at either end of the 452 
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steroid molecule. Thus, it can sulfate free steroids or steroid monosulfates (Cook, et 453 
al. 2009). 454 
A question remains as to whether disulfation is purely a catabolic reaction or if such 455 
steroids could be transportable reservoirs of active hormone precursors, as is likely 456 
the case for DHEA and estrone sulfates. Guerami and co-workers (1988) have 457 
proposed that 21OHPreg-diS is an 11-deoxycorticosterone (DOC) precursor during 458 
pregnancy, particularly since circulating levels of this mineralocorticoid and its 459 
sulfate are increased during gestation (Corsan, Macdonald and Casey 1997). It is 460 
known that the placenta is capable of hydrolyzing 21-sulfates and the enzyme 461 
responsible is the usual STS as 21-desulfation does not occur in STSD (Guerami, et al. 462 
1988). Another possible reservoir for disulfates is 5AD(17β)-diS, potentially a 463 
testosterone or estradiol precursor. This steroid is also subject to STS action in 464 
mammals. In contrast, it is believed that human sulfatases are inactive on 17α- (C19 465 
steroids) or 20S--sulfates, a situation shared with the commercial snail and mollusk 466 
enzymes used for hydrolysis in steroid analysis (Stevenson, et al. 2014). 467 
 468 
In summary, we have provided analytical data on the steroid disulfates through their 469 
measurement as intact molecules by LC-MS/MS, employing CIL scan monitoring. We 470 
have attempted to use these additional members of the steroid metabolome to 471 
distinguish fetal disorders of steroid synthesis. To the best of our knowledge, this is 472 
the first time that direct analysis of steroid disulfates has proved its value for clinical 473 
diagnosis. 474 
The ultimate goal of these studies is the ability to quantify the whole urinary steroid 475 
metabolome as unhydrolyzed conjugates, the monosulfates, disulfates, glucuronides 476 
and mixed sulfate-glucuronide conjugates. Studies of the plasma steroid 477 
metabolome should also be included. To achieve this goal will require the synthesis 478 
of a multitude of authentic steroids including appropriate internal standards and an 479 
improvement in chromatographic resolution. 480 
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FIGURE LEGENDS 
 
Figure 1 
Chromatographic separation obtained for (A) seven synthesized isomers 
of pregnanediol disulfates and (B) androsterone and etiocholanolone 
glucuronide. Note that the method optimized for the separation of 
isomeric disulfate metabolites was not able to separate epimeric 
glucuronides. 
 
Figure 2 
Steroid synthesis in STSD pregnancy starting from fetal adrenal 
pregnenolone. Inactivity of STS prevents conversion of 16αOHDHEA-S to 
estriol in placenta so the former (and its metabolites) is excreted as 
sulfates by mother. C21 steroid sulfates upstream from 16αOHDHEA-S also 
pass the placenta without de-sulfation and are directly excreted in 
maternal urine.  
 
Figure 3  
Selected urinary ∆
5
 steroid sulfate and estriol conjugate analysis in a 
control and STSD affected pregnancy. Note the markedly increased  ∆
5 
steroid mono and disulfates in STSD. Regarding the estriol conjugates it 
must be noted that glucuronides give lower MS transition responses than 
sulfates under the reported conditions.  In reality, E3-S is a minor 
metabolite of estriol compared to the 3- and 16-glucuronides, although it 
appears contrary in the chromatograms.  
 
Figure 4 
Panel A: Ratios of steroid sulfates to E3 glucuronide (3+16) in STSD. The 
scale represents the ratios of raw peak areas of transitions, not the actual 
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amount quantified. All ratios show separation of controls from affected 
pregnancies. Panel B: a measure of the difference between the lowest 
STSD ratio and highest control ratio. The higher this value, the greater the 
separation between affected and normal. Two ∆
5
 pregnene di-sulfates are 
the most efficacious diagnostic analytes. Panel C: combining data from 
5PD-diS and 21OHPreg-diS increases discrimination between normal and 
STSD. 
 
Figure 5 
Steroid biosynthesis and metabolism in PORD and normal pregnancies and 
neonates. Normal pregnancy: fetal adrenal pregnenolone is converted to 
maternally excreted estriol conjugates (POR essential). PORD pregnancy: 
excess adrenal pregnenolone (due to PORD) is metabolized primarily to 
maternally excreted 3β5αPD-diS. Normal neonate: Excretion product 
16αOHDHEA-S and other sulfates. PORD neonate: major pregnenolone 
excretory product 5PD-diS.  
 
Figure 6  
Selected Reaction Monitoring (SRM) transition chromatograms of estriol 
conjugates and steroid disulfates in control (A) and PORD affected 
pregnancies (B). Note high excretion of 3β5αPD-diS and 21OHPreg3β5α-
diS. (C) Graph shows peak area ratios (analyte/E3-G) for 2 affected 
pregnancies and 11 controls. 
 
Figure 7. 
SRM chromatograms of control (A) and affected PORD babies (B). The key 
analyte is the pregnenolone metabolite 5PD-diS and its relative excess is 
determined by peak area ratio to 16αOHDHEA-S, normally a dominant 
metabolite in neonates. Discrimination obtained by the use of 5PD-
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diS/16αOHDHEA-S (C) and 21OHPreg-diS/16αOHDHEA-S (D) between 
healthy and PORD babies.  
 
Figure 8. 
Deficiency of 7-dehydrosterol reductase (DHCR7, SLOS] causes 7-or 8-
dehydro-cholesterol to be used as fetal precursor for downstream steroids 
which retain B- ring unsaturation. Dehydro-pregnanetriol (DHPT) and 
dehydroestriol (DHE3) glucuronides have been used classically for 
diagnosis but here are candidate disulfates tentatively identified, 
compounds not seen in controls. 
 
Figure 9. 
SRM chromatograms of candidate analytes in SLOS pregnancy. (A) control 
pregnancy and (B) affected pregnancy. Transition chromatograms for 
known diagnostic steroid glucuronides and candidate disulfates useful for 
diagnosis. While authentic steroids are not available, these steroids, with 
appropriate transitions were only present in affected pregnancies. Steroid 
A/B ring stereochemistry including ∆7/∆8 unsaturation is as yet unknown. 
In the control chromatograms E3 conjugates are shown but all SLOS 
candidate disulfates and glucuronides are absent. 
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 Table 1. SRM parameters of selected steroids 
Analyte Disorder MW Retention 
time 
(min) 
Precursor 
ion (m/z) 
Product 
ion (m/z) 
Collision 
energy 
(eV) 
Monoconjugates       
E3-3G all 464 2.3 463 287 30 
E3-16G all 464 9.3 463 287 30 
E3-3S all 368 7.3 367 287 35 
16OHDHEA-S STSD/PORD* 384 16.0 383 97 40 
DHE3-G SLOS 462 8.6/9.1 461 285 30 
DHPT-G SLOS 510 21.3 509 75 30 
Disulfates       
5AD(17α)-diS STSD 450 15.5 224 351 15 
5AD(17β)-diS STSD 450 13.4 224 351 15 
16αOHDHEA-diS STSD 464 10.0 231 365 15 
16βOHDHEA-diS STSD 464 8.2 231 365 15 
5PT-diS STSD 494 10.5 246 395 15 
21OHPreg-diS STSD/PORD 492 18.2 245 393 15 
5PD-diS STSD/PORD* 478 16.7 238 379 15 
3β5αPD-diS PORD 480 17.6 239 381 15 
DH5AD-diS SLOS 448 11.4 223 349 15 
DHPT-diS SLOS 494 12.6 246 395 15 
DHPD-diS SLOS 478 15.6 238 379 15 
* PORD neonatal 
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